SOURCE: BioCentury; Thomson Reuters

NewsMakers in the Biotech Industry

October 22, 2010 06:00 ET

Thomson Reuters and BioCentury Convene NewsMakers in the Biotech Industry Today in New York

37 Companies Offer Tier-Jumping Potential Going Into 2011 on Robust Flow of Clinical, Regulatory and Earnings News

NEW YORK, NY--(Marketwire - October 22, 2010) -  BioCentury and Thomson Reuters today convene the 17th Annual NewsMakers in the Biotech Industry in New York City. The conference showcases 37 public life science companies independently selected to present on the basis of key clinical, regulatory and commercial milestones that will drive valuations going into 2011.
More than 700 delegates, including top life science investment professionals and pharmaceutical business development and licensing executives, pre-registered for the conference at the Millennium Broadway Hotel and Conference Center in New York City.

The NewsMakers companies are pace setters in the current biotech market, collectively up 17% year-to-date, compared with the 15% jump in the BioCentury 100 Index and the 10% gain in the NASDAQ Biotechnology Index (NBI). Over that same period, the aggregate market cap of the NewsMakers companies increased from $12.9 billion to $15 billion.

In its 4Q Financial Markets Preview, BioCentury noted that with at least a half dozen biotech PDUFA dates coming up, buysiders are looking at a busy quarter that could lay the foundation for companies to jump one or more market cap tiers. The NewsMakers Class of 2010 offers candidates aiming to make the leap.

The NewsMakers have 27 marketed products, including 18 therapeutics and nine diagnostics; seven compounds under regulatory review; 39 Phase III trials underway; and more than 1,800 more clinical trials in the pipeline.

The disease space covers cancer, infectious diseases and neurology, plus inflammatory, autoimmune, gastrointestinal, cardiovascular and metabolic disorders.

Collectively, the NewsMakers Class of 2010 has raised $10.4 billion in capital, including $2.2 billion since the beginning of 2009.

Money managers in attendance at NewsMakers control $464.3 billion in equity assets, $56.4 billion in healthcare assets, and $14.7 billion in biotech assets.

The 2010 NewsMakers Presenting Companies

Today's presenting companies were screened using Thomson Reuters and BioCentury's industry analysis and proprietary databases, including BioCentury's BCIQ online business intelligence platform. The result is an independently selected mix of companies with key near-term clinical, regulatory and clinical milestones.

Acorda Therapeutics Inc. (ACOR)   Keryx Biopharmaceuticals Inc. (KERX)
Amarin Corp. plc (AMRN)   Lexicon Pharmaceuticals Inc. (LXRX)
Ariad Pharmaceuticals Inc. (ARIA)   The Medicines Co. (MDCO)
AVI BioPharma Inc. (AVII)   Medivation Inc. (MDVN)
BioSpecifics Technologies Corp. (BSTC)   Micromet Inc. (MITI)
Celldex Therapeutics Inc. (CLDX)   Momenta Pharmaceuticals Inc. (MNTA)
Chelsea Therapeutics International Ltd. (CHTP)   Neoprobe Corp. (NEOP)
Cleveland BioLabs Inc. (CBLI)   NPS Pharmaceuticals Inc. (NPSP)
Clinical Data Inc. (CLDA)   Omeros Corp. (OMER)
Columbia Laboratories Inc. (CBRX)   Pharmacyclics Inc. (PCYC)
Depomed Inc. (DEPO)   PolyMedix Inc. (PYMX)
Dynavax Technologies Corp. (DVAX)   Regeneron Pharmaceuticals Inc. (REGN)
Emergent BioSolutions Inc. (EBS)   Resverlogix Corp. (RVX)
Exelixis Inc. (EXEL)   Synta Pharmaceuticals Corp. (SNTA)
Geron Corp. (GERN)   Transcept Pharmaceuticals Inc. (TSPT)
GTx Inc. (GTXI)   Vical Inc. (VICL)
Idera Pharmaceuticals Inc. (IDRA)   Xoma Ltd. (XOMA)
ImmunoGen Inc. (IMGN)   Ziopharm Oncology Inc. (ZIOP)
Isis Pharmaceuticals Inc. (ISIS)     

See the Presenting Company schedule

Sponsors Demonstrate Long-Term Commitment to Industry

The 2010 Sponsors of NewsMakers in the Biotech Industry are William Blair & Company; Ladenburg Thalmann; Rodman & Renshaw; Torreya Partners; WBB Securities; Wedbush Pacific Growth; WJB Capital Group; and Yorkville Advisors.

This premier Wall Street event is one of two annual investor conferences organized by BioCentury and Thomson Reuters. The next conference, Future Leaders in the Biotech Industry, will take place in New York City in April 2011.

About BioCentury
BioCentury Publications, Inc. provides essential biopharma industry intelligence from five offices in the U.S. and Europe. For more than 18 years, a global audience of biotech and pharmaceutical executives and investors has benefited from BioCentury's deep knowledge, data-driven analysis, independent perspective and trustworthy content available through the company's publications, data products and collaborative industry conferences in the U.S., Europe and Asia. BioCentury's titles include the flagship BioCentury, the Bernstein Report on BioBusiness; its SciBX: Science-Business eXchange translational science joint publishing venture with Nature Publishing Group; and its BioCentury Extra online daily newspaper. These timely journals are backed by BCIQ: BioCentury Online Intelligence, an online business intelligence resource. The company also produces the weekly "BioCentury this Week" TV program, a partnership with the Gannett-owned CBS affiliate W*USA Channel 9 in Washington, D.C. For more information, visit and

About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs 55,000 people and operates in over 100 countries. For more information, go to

BioCentury®; The Bernstein Report on BioBusiness™ and BCIQ are trademarks of BioCentury Publications, Inc. SciBX and SciBX: Science-Business eXchange are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.

Contact Information

  • Contact:
    Thomas C. Carey
    Vice President of Commercial Operations
    BioCentury Publications, Inc.
    +1 650 595-5333
    Email Contact